Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context

Flavio Nobili, Annachiara Cagnin, Maria L. Calcagni, Andrea Chincarini, Ugo P. Guerra, Silvia Morbelli, Alessandro Padovani, Barbara Paghera, Sabina Pappatà, Lucilla Parnetti, Stelvio Sestini, Orazio Schillaci

Research output: Contribution to journalArticle

Abstract

In May 2017 some representatives of the Italian nuclear medicine and neurological communities spontaneously met to discuss the issues emerged during the first two years of routine application of amyloid PET with fluorinated radiopharmaceuticals in the real world. The limitations of a binary classification of scans, the possibility to obtain early images as a surrogate marker of regional cerebral bloos flow, the need for (semi-)quantification and, thus, the opportunity of ranking brain amyloidosis, the correlation with Aβ42 levels in the cerebrospinal fluid, the occurrence and biological meaning of uncertain/boderline scans, the issue of incidental amyloidosis, the technical pittfalls leading to false negative/positive results, the position of the tool in the diagnostic flow-chart in the national reality, are the main topics that have been discussed. Also, a card to justify the examination to be filled by the dementia specialist and a card for the nuclear medicine physician to report the exam in detail have been approved and are available in the web, which should facilitate the creation of a national register, as previewed by the 2015 intersocietal recommendation on the use of amyloid PET in Italy. The content of this discussion could stimulate both public institutions and companies to support further research on these topics.

Fingerprint

Nuclear Medicine
Amyloidosis
Amyloid
Radiopharmaceuticals
Italy
Cerebrospinal Fluid
Dementia
Biomarkers
Physicians
Brain
Research

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context. / Nobili, Flavio; Cagnin, Annachiara; Calcagni, Maria L.; Chincarini, Andrea; Guerra, Ugo P.; Morbelli, Silvia; Padovani, Alessandro; Paghera, Barbara; Pappatà, Sabina; Parnetti, Lucilla; Sestini, Stelvio; Schillaci, Orazio.

In: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.., Vol. 63, No. 1, 01.03.2019, p. 83-92.

Research output: Contribution to journalArticle

@article{f20b0045f42547f8aa041e9d4ef4370c,
title = "Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context",
abstract = "In May 2017 some representatives of the Italian nuclear medicine and neurological communities spontaneously met to discuss the issues emerged during the first two years of routine application of amyloid PET with fluorinated radiopharmaceuticals in the real world. The limitations of a binary classification of scans, the possibility to obtain early images as a surrogate marker of regional cerebral bloos flow, the need for (semi-)quantification and, thus, the opportunity of ranking brain amyloidosis, the correlation with Aβ42 levels in the cerebrospinal fluid, the occurrence and biological meaning of uncertain/boderline scans, the issue of incidental amyloidosis, the technical pittfalls leading to false negative/positive results, the position of the tool in the diagnostic flow-chart in the national reality, are the main topics that have been discussed. Also, a card to justify the examination to be filled by the dementia specialist and a card for the nuclear medicine physician to report the exam in detail have been approved and are available in the web, which should facilitate the creation of a national register, as previewed by the 2015 intersocietal recommendation on the use of amyloid PET in Italy. The content of this discussion could stimulate both public institutions and companies to support further research on these topics.",
author = "Flavio Nobili and Annachiara Cagnin and Calcagni, {Maria L.} and Andrea Chincarini and Guerra, {Ugo P.} and Silvia Morbelli and Alessandro Padovani and Barbara Paghera and Sabina Pappat{\`a} and Lucilla Parnetti and Stelvio Sestini and Orazio Schillaci",
year = "2019",
month = "3",
day = "1",
doi = "10.23736/S1824-4785.18.03069-8",
language = "English",
volume = "63",
pages = "83--92",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context

AU - Nobili, Flavio

AU - Cagnin, Annachiara

AU - Calcagni, Maria L.

AU - Chincarini, Andrea

AU - Guerra, Ugo P.

AU - Morbelli, Silvia

AU - Padovani, Alessandro

AU - Paghera, Barbara

AU - Pappatà, Sabina

AU - Parnetti, Lucilla

AU - Sestini, Stelvio

AU - Schillaci, Orazio

PY - 2019/3/1

Y1 - 2019/3/1

N2 - In May 2017 some representatives of the Italian nuclear medicine and neurological communities spontaneously met to discuss the issues emerged during the first two years of routine application of amyloid PET with fluorinated radiopharmaceuticals in the real world. The limitations of a binary classification of scans, the possibility to obtain early images as a surrogate marker of regional cerebral bloos flow, the need for (semi-)quantification and, thus, the opportunity of ranking brain amyloidosis, the correlation with Aβ42 levels in the cerebrospinal fluid, the occurrence and biological meaning of uncertain/boderline scans, the issue of incidental amyloidosis, the technical pittfalls leading to false negative/positive results, the position of the tool in the diagnostic flow-chart in the national reality, are the main topics that have been discussed. Also, a card to justify the examination to be filled by the dementia specialist and a card for the nuclear medicine physician to report the exam in detail have been approved and are available in the web, which should facilitate the creation of a national register, as previewed by the 2015 intersocietal recommendation on the use of amyloid PET in Italy. The content of this discussion could stimulate both public institutions and companies to support further research on these topics.

AB - In May 2017 some representatives of the Italian nuclear medicine and neurological communities spontaneously met to discuss the issues emerged during the first two years of routine application of amyloid PET with fluorinated radiopharmaceuticals in the real world. The limitations of a binary classification of scans, the possibility to obtain early images as a surrogate marker of regional cerebral bloos flow, the need for (semi-)quantification and, thus, the opportunity of ranking brain amyloidosis, the correlation with Aβ42 levels in the cerebrospinal fluid, the occurrence and biological meaning of uncertain/boderline scans, the issue of incidental amyloidosis, the technical pittfalls leading to false negative/positive results, the position of the tool in the diagnostic flow-chart in the national reality, are the main topics that have been discussed. Also, a card to justify the examination to be filled by the dementia specialist and a card for the nuclear medicine physician to report the exam in detail have been approved and are available in the web, which should facilitate the creation of a national register, as previewed by the 2015 intersocietal recommendation on the use of amyloid PET in Italy. The content of this discussion could stimulate both public institutions and companies to support further research on these topics.

UR - http://www.scopus.com/inward/record.url?scp=85061962828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061962828&partnerID=8YFLogxK

U2 - 10.23736/S1824-4785.18.03069-8

DO - 10.23736/S1824-4785.18.03069-8

M3 - Article

AN - SCOPUS:85061962828

VL - 63

SP - 83

EP - 92

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 1

ER -